Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1992 Sep 1;89(17):8087–8091. doi: 10.1073/pnas.89.17.8087

S-nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme.

J S Stamler 1, D I Simon 1, O Jaraki 1, J A Osborne 1, S Francis 1, M Mullins 1, D Singel 1, J Loscalzo 1
PMCID: PMC49861  PMID: 1325644

Abstract

Tissue-type plasminogen activator (t-PA) reacts upon exposure to endothelium-derived relaxing factor (EDRF) by way of the enzyme's single free sulfhydryl (Cys-83) to form a stable S-nitrosothiol protein adduct. S-nitrosylation endows t-PA with potent vasodilatory and antiplatelet properties that are accompanied by elevations in intracellular cyclic GMP analogous to those induced by low molecular weight (e.g., S-nitroso amino acid) S-nitrosothiols. Moreover, this chemical modification does not adversely affect the catalytic efficiency of t-PA, the fibrin stimulation of this activity, the binding of t-PA to fibrinogen, or the interaction of the enzyme with its physiologic serine protease inhibitor, plasminogen-activator inhibitor type I. The coupling of vasodilatory, antiplatelet, and fibrinolytic properties in one molecule makes the S-nitrosylated t-PA a unique molecular species and may provide insight into the mechanisms by which the endothelium maintains vessel patency. These data also suggest a pharmacologic approach to treatment of thromboocclusive disorders.

Full text

PDF
8087

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azuma H., Ishikawa M., Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol. 1986 Jun;88(2):411–415. doi: 10.1111/j.1476-5381.1986.tb10218.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BORN G. V., CROSS M. J. THE AGGREGATION OF BLOOD PLATELETS. J Physiol. 1963 Aug;168:178–195. doi: 10.1113/jphysiol.1963.sp007185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bonnett R., Holleyhead R., Johnson B. L., Randall E. W. Reaction of acidified nitrite solutions with peptide derivatives: evidence for nitrosamine and thionitrite formation from 15N N.m.r. studies. J Chem Soc Perkin 1. 1975;(22):2261–2241. doi: 10.1039/p19750002261. [DOI] [PubMed] [Google Scholar]
  4. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost. 1980 Jun 18;43(2):77–89. [PubMed] [Google Scholar]
  5. Davies P. F., Truskey G. A., Warren H. B., O'Connor S. E., Eisenhaure B. H. Metabolic cooperation between vascular endothelial cells and smooth muscle cells in co-culture: changes in low density lipoprotein metabolism. J Cell Biol. 1985 Sep;101(3):871–879. doi: 10.1083/jcb.101.3.871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  7. Gold H. K. Conjunctive antithrombotic and thrombolytic therapy for coronary-artery occlusion. N Engl J Med. 1990 Nov 22;323(21):1483–1485. doi: 10.1056/NEJM199011223232110. [DOI] [PubMed] [Google Scholar]
  8. Hawiger J., Parkinson S., Timmons S. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets. Nature. 1980 Jan 10;283(5743):195–197. doi: 10.1038/283195a0. [DOI] [PubMed] [Google Scholar]
  9. Ignarro L. J., Buga G. M., Wood K. S., Byrns R. E., Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9265–9269. doi: 10.1073/pnas.84.24.9265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ignarro L. J., Lippton H., Edwards J. C., Baricos W. H., Hyman A. L., Kadowitz P. J., Gruetter C. A. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther. 1981 Sep;218(3):739–749. [PubMed] [Google Scholar]
  11. Lidbury P. S., Korbut R., Vane J. R. Sodium nitroprusside modulates the fibrinolytic system in the rabbit. Br J Pharmacol. 1990 Nov;101(3):527–530. doi: 10.1111/j.1476-5381.1990.tb14115.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lieberman E. H., O'Neill S., Mendelsohn M. E. S-nitrosocysteine inhibition of human platelet secretion is correlated with increases in platelet cGMP levels. Circ Res. 1991 Jun;68(6):1722–1728. doi: 10.1161/01.res.68.6.1722. [DOI] [PubMed] [Google Scholar]
  13. Loscalzo J., Braunwald E. Tissue plasminogen activator. N Engl J Med. 1988 Oct 6;319(14):925–931. doi: 10.1056/NEJM198810063191407. [DOI] [PubMed] [Google Scholar]
  14. Loscalzo J., Smick D., Andon N., Cooke J. S-nitrosocaptopril. I. Molecular characterization and effects on the vasculature and on platelets. J Pharmacol Exp Ther. 1989 Jun;249(3):726–729. [PubMed] [Google Scholar]
  15. Loscalzo J. Structural and kinetic comparison of recombinant human single- and two-chain tissue plasminogen activator. J Clin Invest. 1988 Oct;82(4):1391–1397. doi: 10.1172/JCI113743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Loscalzo J., Vaughan D. E. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest. 1987 Jun;79(6):1749–1755. doi: 10.1172/JCI113015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Marder V. J., Sherry S. Thrombolytic therapy: current status (1). N Engl J Med. 1988 Jun 9;318(23):1512–1520. doi: 10.1056/NEJM198806093182306. [DOI] [PubMed] [Google Scholar]
  18. Mellion B. T., Ignarro L. J., Ohlstein E. H., Pontecorvo E. G., Hyman A. L., Kadowitz P. J. Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood. 1981 May;57(5):946–955. [PubMed] [Google Scholar]
  19. Myers P. R., Minor R. L., Jr, Guerra R., Jr, Bates J. N., Harrison D. G. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature. 1990 May 10;345(6271):161–163. doi: 10.1038/345161a0. [DOI] [PubMed] [Google Scholar]
  20. Niewiarowski S., Senyi A. F., Gillies P. Plasmin-induced platelet aggregation and platelet release reaction. Effects on hemostasis. J Clin Invest. 1973 Jul;52(7):1647–1659. doi: 10.1172/JCI107345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Palmer R. M., Ferrige A. G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987 Jun 11;327(6122):524–526. doi: 10.1038/327524a0. [DOI] [PubMed] [Google Scholar]
  22. Runge M. S., Quertermous T., Haber E. Plasminogen activators. The old and the new. Circulation. 1989 Feb;79(2):217–224. doi: 10.1161/01.cir.79.2.217. [DOI] [PubMed] [Google Scholar]
  23. Rånby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta. 1982 Jun 24;704(3):461–469. doi: 10.1016/0167-4838(82)90068-1. [DOI] [PubMed] [Google Scholar]
  24. Schwartz S. M. Selection and characterization of bovine aortic endothelial cells. In Vitro. 1978 Dec;14(12):966–980. doi: 10.1007/BF02616210. [DOI] [PubMed] [Google Scholar]
  25. Simon D. I., Fless G. M., Scanu A. M., Loscalzo J. Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein. Biochemistry. 1991 Jul 9;30(27):6671–6677. doi: 10.1021/bi00241a006. [DOI] [PubMed] [Google Scholar]
  26. Sobel B. E., Sarnoff S. J., Nachowiak D. A. Augmented and sustained plasma concentrations after intramuscular injections of molecular variants and deglycosylated forms of tissue-type plasminogen activators. Circulation. 1990 Apr;81(4):1362–1373. doi: 10.1161/01.cir.81.4.1362. [DOI] [PubMed] [Google Scholar]
  27. Stamler J. S., Simon D. I., Osborne J. A., Mullins M. E., Jaraki O., Michel T., Singel D. J., Loscalzo J. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):444–448. doi: 10.1073/pnas.89.1.444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Stamler J. S., Vaughan D. E., Loscalzo J. Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin. Circ Res. 1989 Sep;65(3):796–804. doi: 10.1161/01.res.65.3.796. [DOI] [PubMed] [Google Scholar]
  29. Stamler J., Mendelsohn M. E., Amarante P., Smick D., Andon N., Davies P. F., Cooke J. P., Loscalzo J. N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res. 1989 Sep;65(3):789–795. doi: 10.1161/01.res.65.3.789. [DOI] [PubMed] [Google Scholar]
  30. Vane J. R., Anggård E. E., Botting R. M. Regulatory functions of the vascular endothelium. N Engl J Med. 1990 Jul 5;323(1):27–36. doi: 10.1056/NEJM199007053230106. [DOI] [PubMed] [Google Scholar]
  31. Wink D. A., Kasprzak K. S., Maragos C. M., Elespuru R. K., Misra M., Dunams T. M., Cebula T. A., Koch W. H., Andrews A. W., Allen J. S. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science. 1991 Nov 15;254(5034):1001–1003. doi: 10.1126/science.1948068. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES